Insider Buying: ImmuCell (NASDAQ:ICCC) CEO Acquires $75,920.00 in Stock

ImmuCell Corporation (NASDAQ:ICCC) CEO Boekhorst Paul Francis Oliv Te purchased 8,000 shares of ImmuCell stock in a transaction on Thursday, June 18th. The shares were acquired at an average price of $9.49 per share, with a total value of $75,920.00. Following the transaction, the chief executive officer directly owned 17,785 shares in the company, valued at $168,779.65. This trade represents a 81.76% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ImmuCell Price Performance

ICCC opened at $9.79 on Thursday. The firm has a market capitalization of $88.60 million, a P/E ratio of -163.14 and a beta of 0.55. The stock has a fifty day moving average of $9.13 and a 200-day moving average of $7.32. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24. ImmuCell Corporation has a 12-month low of $4.52 and a 12-month high of $10.75.

ImmuCell (NASDAQ:ICCC) last released its earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. The firm had revenue of $10.36 million during the quarter, compared to analyst estimates of $5.40 million. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%.

Institutional Trading of ImmuCell

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 2,907 shares during the period. Steadtrust LLC lifted its position in shares of ImmuCell by 79.1% during the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 25,070 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of ImmuCell by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 1,749 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in shares of ImmuCell by 199.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 24,303 shares in the last quarter. Finally, Militia Capital Management LLC bought a new position in shares of ImmuCell in the first quarter worth $114,000. Institutional investors and hedge funds own 13.47% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings cut ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.